Michael Girschikofsky
Overview
Explore the profile of Michael Girschikofsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1437
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Strassl I, Nikoloudis A, Machherndl-Spandl S, Buxhofer-Ausch V, Binder M, Wipplinger D, et al.
Cancers (Basel)
. 2023 Dec;
15(24).
PMID: 38136284
Background: Despite major treatment advances, multiple myeloma remains incurable. The outcome of patients who are refractory to immunomodulatory agents, proteasome inhibitors, and anti-CD38 monoclonal antibodies is poor, and improved treatment...
2.
Nikoloudis A, Neumann I, Buxhofer-Ausch V, Machherndl-Spandl S, Binder M, Kaynak E, et al.
Vaccines (Basel)
. 2023 Oct;
11(10).
PMID: 37896938
(1) Background: mRNA COVID-19 vaccines are effective but show varied efficacy in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HSCT) recipients. (2) Methods: A retrospective study on 167 HSCT...
3.
Pleyer L, Vaisband M, Drost M, Pfeilstocker M, Stauder R, Heibl S, et al.
Am J Hematol
. 2023 Aug;
98(11):1685-1698.
PMID: 37548390
The current gold standard of response assessment in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) is morphologic complete remission (CR) and CR with...
4.
Panje C, Hayoz S, Eisterer W, Hess V, Thuss-Patience P, Schacher S, et al.
Eur J Cancer
. 2022 Nov;
177:186-193.
PMID: 36368252
Background: Recurrent oesophageal cancer after the initial curative multimodality treatment is a disease condition with a poor prognosis. There is limited evidence on recurrence patterns and on the optimal therapeutic...
5.
Leisch M, Pfeilstocker M, Stauder R, Heibl S, Sill H, Girschikofsky M, et al.
Cancers (Basel)
. 2022 May;
14(10).
PMID: 35626063
Azacitidine is the treatment backbone for patients with acute myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia who are considered unfit for intensive chemotherapy. Detailed reports on adverse events in...
6.
Machherndl-Spandl S, Vockenhuber T, Binder M, Weltermann A, Apfalter P, Lass-Florl C, et al.
Leuk Lymphoma
. 2022 May;
63(10):2330-2335.
PMID: 35561263
Invasive fungal infections (IFIs) are commonly observed in patients, who are at high risk of severe infections during the neutropenic phase. The aim of this retrospective single-center study was to...
7.
Goyal G, Tazi A, Go R, Rech K, Picarsic J, Vassallo R, et al.
Blood
. 2022 Mar;
139(17):2601-2621.
PMID: 35271698
Langerhans cell histiocytosis (LCH) can affect children and adults with a wide variety of clinical manifestations, including unifocal, single-system multifocal, single-system pulmonary (smoking-associated), or multisystem disease. The existing paradigms in...
8.
Goyal G, Heaney M, Collin M, Cohen-Aubart F, Vaglio A, Durham B, et al.
Blood
. 2020 Mar;
135(22):1929-1945.
PMID: 32187362
Erdheim-Chester disease (ECD) is a rare histiocytosis that was recently recognized as a neoplastic disorder owing to the discovery of recurrent activating MAPK (RAS-RAF-MEK-ERK) pathway mutations. Typical findings of ECD...
9.
Schlenk R, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik V, et al.
J Clin Oncol
. 2019 Dec;
38(6):623-632.
PMID: 31851556
Purpose: High CD33 expression in acute myeloid leukemia (AML) with mutated provides a rationale for the evaluation of gemtuzumab ozogamicin (GO) in this AML entity. We conducted a randomized trial...
10.
La Rosee P, Horne A, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N, et al.
Blood
. 2019 Apr;
133(23):2465-2477.
PMID: 30992265
Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome induced by aberrantly activated macrophages and cytotoxic T cells. The primary (genetic) form, caused by mutations affecting lymphocyte cytotoxicity and immune regulation,...